Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. Keeping that in mind, here are two profitable companies that balance growth and profitability and one that may struggle to keep up.
One Stock to Sell:
Royal Caribbean (RCL)
Trailing 12-Month GAAP Operating Margin: 27.3%
Established in 1968, Royal Caribbean Cruises (NYSE: RCL) is a global cruise vacation company renowned for its innovative and exciting cruise experiences.
Why Are We Out on RCL?
- Performance surrounding its passenger cruise days has lagged its peers
- Low free cash flow margin of 8.8% for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
- Low returns on capital reflect management’s struggle to allocate funds effectively
Royal Caribbean’s stock price of $323.79 implies a valuation ratio of 17.1x forward P/E. To fully understand why you should be careful with RCL, check out our full research report (it’s free).
Two Stocks to Watch:
Doximity (DOCS)
Trailing 12-Month GAAP Operating Margin: 33.3%
With over 80% of U.S. physicians as members of its digital community, Doximity (NYSE: DOCS) operates a digital platform that enables physicians and other healthcare professionals to collaborate, stay current with medical news, manage their careers, and conduct virtual patient visits.
Why Does DOCS Stand Out?
- Annual revenue growth of 25.5% over the last five years beat the sector average and indicates its software solves complex business issues
- Superior software functionality and low servicing costs are reflected in its best-in-class gross margin of 89.1%
- Software platform has product-market fit given the rapid recovery of its customer acquisition costs
At $21.71 per share, Doximity trades at 6.2x forward price-to-sales. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.
Boston Scientific (BSX)
Trailing 12-Month GAAP Operating Margin: 19.8%
Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE: BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.
Why Do We Like BSX?
- Average organic revenue growth of 15.8% over the past two years demonstrates its ability to expand independently without relying on acquisitions
- Incremental sales over the last five years have been highly profitable as its earnings per share increased by 18.6% annually, topping its revenue gains
- Free cash flow margin jumped by 12.4 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
Boston Scientific is trading at $46.12 per share, or 13.7x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
